Aclaris Therapeutics, Inc. has grown revenue −36% a year over three years and 4.4% a year over five. Revenue growth, 3-year annual rate: −36% (Biotechnology median +17%). Revenue growth, 5-year rate: +4.4%, growth has slowed since the five-year average. Years of annual history on file: 13, FY2013 to FY2025, as filed.

ACRSAclaris Therapeutics, Inc.

Healthcare

$3.78+105% 1Y

$3.78

$1.8152 weeks$6.54

Is it growing?

Watch

Growth is fading: revenue shrinking (−51% year on year) and operating margin narrowing (−318.3 points).

2 to watch, 1 without data

Revenue trend−51% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +4% a year.

Margin direction−318.3 points operating

Trailing-twelve-month operating margin, -1218.8% now against -900.5% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is ACRS growing?

Aclaris Therapeutics, Inc. has grown revenue −36% a year over three years and 4.4% a year over five.

−36%

Revenue growth, 3-year annual rate · Biotechnology median +17% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +4.4%
Revenue growth, 5-year rate · −36% over three · growth has slowed since the five-year average
Years of annual history on file: 13
Years of annual history on file · FY2013 to FY2025, as filed

Details›